The World Health Organization (WHO) has temporarily suspended a clinical trial of the malaria drug hydroxychloroquine in Covid-19 patients over safety concerns, according to the organisation’s director-general Dr Tedros Adhanom Ghebreyesus.
The move comes after data from an observational study published in The Lancet journal revealed a higher mortality rate in patients treated with hydroxycholoroquine when given alone or with a macrolide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During the observational study, hydroxychloroquine and chloroquine were assessed for their effects on hospitalised Covid-19 patients.
